The sigma-1 (σ1)
receptor, an enigmatic protein
originally classified as an opioid receptor subtype, is now understood
to possess unique structural and functional features of its own and
play critical roles to widely impact signaling transduction by interacting
with receptors, ion channels, lipids, and kinases. The σ1 receptor is implicated in modulating learning, memory, emotion,
sensory systems, neuronal development, and cognition and accordingly
is now an actively pursued drug target for various neurological and
neuropsychiatric disorders. Evaluation of the five selective σ1 receptor drug candidates (pridopidine, ANAVEX2-73, SA4503,
S1RA, and T-817MA) that have entered clinical trials has shown that
reaching clinical approval remains an evasive and important goal.
This review provides up-to-date information on the selective targeting
of σ1 receptors, including their history, function,
reported crystal structures, and roles in neurological diseases, as
well as a useful collation of new chemical entities as σ1 selective orthosteric ligands or allosteric modulators.